AIP
BIIB icon

ARS Investment Partners’s Biogen BIIB Stock Holding History

ARS Investment Partners’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-17
Closed -$5K – 152
2022
Q3 		$5K Buy
+17
New +$3.61K ﹤0.01% 176
2018
Q4 		– Sell
-764
Closed -$270K – 113
2018
Q3 		$270K Buy
764
+9
+1% +$3.1K 0.04% 115
2018
Q2 		$219K Hold
755
– – 0.03% 115
2018
Q1 		$207K Sell
755
-30,858
-98% -$9.58M 0.03% 146
2017
Q4 		$10.1M Buy
31,613
+15,942
+102% +$5.11M 1.22% 30
2017
Q3 		$4.91M Buy
+15,671
New +$4.64M 0.63% 43

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ARS Investment Partners's BIIB Position: Q4 2022 in Review

ARS Investment Partners sold out of Biogen (BIIB) in Q4 2022, closing a stake of 17 shares — an estimated $5K sold.

ARS Investment Partners first reported a position in BIIB in Q3 2017 and held it in 6 quarters. The position peaked at $10.1M in Q4 2017. 1,031 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

  • ARS Investment Partners reported no remaining Biogen position as of Q4 2022 after selling out during the quarter.
  • ARS Investment Partners sold 17 Biogen shares in Q4 2022, an estimated $5K.
  • ARS Investment Partners first reported a position in Biogen in Q3 2017 and held it in 6 quarters.
  • ARS Investment Partners's Biogen position peaked at $10.1M in Q4 2017.
  • 1,031 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on ARS Investment Partners's 13F filing for Q4 2022, filed 25 Jan 2023.